All In Biotech

Drug Trial Radar · NCT05918302

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy With 177Lu-edotreotide Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Oct 27, 2023

Primary completion

Mar 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lumara Bio Oncologics GmbH; MFAR
First posted
Jun 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

Conditions

  • Neuroendocrine Tumors
  • Lung Neuroendocrine Neoplasm
  • Thymus Neoplasms

Interventions

  • 177Lu-edotreotideDrug

    6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide

  • EverolimusDrug

    10 mg orally once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Throughout the study period, approximately 3 years per patient

Locations

27 sites in 4 countries. Site status is shown where the registry gives one.

  • UCL Saint-Luc

    Brussels, Belgium · Recruiting

  • CHU Liège

    Liège, Belgium · Recruiting

  • Antwerp University Hospital (UZA)

    Edegem, Edegem, Belgium · Recruiting

  • Centre Hospitalier Universitaire (CHU) Bordeux

    Bourdeaux, France · Recruiting

  • Lille University Hospital

    Lille, France · Recruiting

  • Hôpital Edouard Herriot, Lyon

    Lyon, France · Recruiting

  • Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, France

    Marseille, France · Recruiting

  • Department of Digestive Oncology, CHU Saint Eloi, Montpellier, France/ ICM Cancer Institute at Montpellier

    Montpellier, France · Recruiting

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France · Recruiting

  • I. Gustave Roussy, Paris

    Paris, France · Recruiting

  • Hospital Center University Dijon Bourgogne (CHU Bourgogne)

    Dijon, Dijon, France · Recruiting

  • AOU Consorziale Policlinico di Bari - CROB Referrall Cancer Center of Basilicata

    Bari, Italy · Recruiting

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Irsì - Meldola

    Meldola, Italy · Recruiting

  • Istituto Europeo di Oncologia - Milano

    Milan, Italy · Recruiting

  • Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence Rome, Rome, Italy.

    Roma, Italy · Not yet recruiting

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Italy · Recruiting

  • Azienda USL IRCCS Di Reggio Emilia

    Reggio Emilia, Reggio Emilia, Italy · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Virgen del Rocío

    Seville, Andalusia, Spain · Recruiting

  • ICO Institut Català d'Oncologia L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

  • Complexo Hospitalario Universitario de Santiago de Compostela

    Santiago de Compostela, Galicia, Spain · Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal, Madrid

    Madrid, Madrid, Spain · Recruiting

  • Fundación Jiménez Díaz University Hospital

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias, Spain · Recruiting

  • Hospital Universitario y Politécnico La Fe

    Valencia, Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.